Top Tardive Dyskinesia Treatment Companies

Global Tardive Dyskinesia Treatment Market size was valued at USD 9.75 Billion in 2023 and is poised to grow from USD 10.11 Billion in 2024 to USD 13.52 Billion by 2032, growing at a CAGR of 3.7% during the forecast period (2025-2032).

Tardive dyskinesia treatment providers should focus on investing in R&D to develop new therapeutics and treatments. Working with government organizations and health non-profits can also expand the business scope for market players. Developing treatment with minimal side effects is a key opportunity as per the global tardive dyskinesia treatment market analysis. 'Teva Pharmaceutical Industries Ltd.', 'Neurocrine Biosciences Inc.', 'Medicure Inc.', 'Mylan N.V', 'Dr. Reddy’s Laboratories Ltd.', 'Sun Pharmaceutical Industries Ltd. ', 'Bionpharma', 'Hetero', 'Bausch Health', 'Sanofi', 'Johnson & Johnson Services Inc.', 'GlaxoSmithKline Plc.', 'Lupin Pharmaceuticals Inc.', 'Lilly', 'Novartis AG'

Regulatory agencies, notably the U.S. Food and Drug Administration (FDA), have adopted expedited pathways for TD treatments, recognizing the unmet medical need. Fast-track designations and priority reviews facilitate quicker market entry for promising therapies. This regulatory support incentivizes pharmaceutical companies to invest in TD drug development and favors the global tardive dyskinesia treatment market outlook as well.

Advancements in VMAT2 Inhibitor Therapies: The development and approval of vesicular monoamine transporter 2 (VMAT2) inhibitors, such as valbenazine (Ingrezza) and deutetrabenazine (Austedo), have revolutionized TD treatment. These medications specifically target the underlying mechanisms of TD, offering improved efficacy and safety profiles compared to traditional therapies. The introduction of alternative formulations, like Ingrezza Sprinkle, caters to patients with swallowing difficulties, enhancing treatment adherence. Hence, focusing on advancement of therapies is slated to be a top tardive dyskinesia treatment market trend in the long run.

Why is the Adoption Rate of Tardive Dyskinesia Treatment High in North America?